BNP Paribas Financial Markets’s Jasper Therapeutics JSPR Stock Holding History

BNP Paribas Financial Markets’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59	Hold	141	–	–	﹤0.01%	5821
2026 Q1	$124	Hold	141	–	–	﹤0.01%	5662
2025 Q4	$258	Hold	141	–	–	﹤0.01%	5543
2025 Q3	$336	Sell	141 -140	-50%	-$425	﹤0.01%	5340
2025 Q2	$1.56K	Sell	281 -14,527	-98%	-$71.5K	﹤0.01%	5103
2025 Q1	$63.7K	Buy	14,808 +11,920	+413%	+$79.3K	﹤0.01%	4206
2024 Q4	$61.7K	Buy	2,888 +376	+15%	+$7.83K	﹤0.01%	4341
2024 Q3	$47.3K	Buy	2,512 +1,698	+209%	+$33.8K	﹤0.01%	3620
2024 Q2	$18.5K	Buy	+814	New	+$19.5K	﹤0.01%	3652

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's JSPR Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 141 shares worth $59. The position accounts for ﹤0.01% of the portfolio, ranked #5821.

BNP Paribas Financial Markets first reported a position in JSPR in Q2 2024 and has held it in 9 quarters since. The position peaked at $63.7K in Q1 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

BNP Paribas Financial Markets held 141 shares of Jasper Therapeutics worth $59 as of Q2 2026.
BNP Paribas Financial Markets left its Jasper Therapeutics share count unchanged in Q2 2026.
Jasper Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5821 holding.
BNP Paribas Financial Markets first reported a position in Jasper Therapeutics in Q2 2024 and has held it in 9 quarters since.
BNP Paribas Financial Markets's Jasper Therapeutics position peaked at $63.7K in Q1 2025.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.